X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to advance LMN-201, an investigational, orally delivered biologic drug to treat and prevent C. difficile infection, through late-stage trials.
Lead Product(s): LMN-201
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-201
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $16.2 million Upfront Cash: Undisclosed
Deal Type: Funding October 17, 2023
Details:
The funds will develop and test a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of viral respiratory infections. The therapeutic is a human immune signaling protein, important in the body's immune response to respiratory viral infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $8.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2023
Details:
Due to synergy LMN-201 antibody cocktail, which targets C. difficile exotoxin B, is 300- to 3000-fold more potent at neutralizing most clinically prevalent TcdB toxin types than bezlotoxumab, only monoclonal antibody currently approved for treatment or prevention of CDI.
Lead Product(s): LMN-201
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-201
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
LMN-101, a VHH-derived binding protein obtained from Spirulina designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni to treat Campylobacter Infections.
Lead Product(s): LMN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The support is provided by the US Army Medical Research and Development Command (USAMRDC) for preclinical development of LMN-301, an investigational product directed at treating and preventing the gastrointestinal (GI) manifestations of Covid-19.
Lead Product(s): LMN-301
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-301
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: USAMRDC
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2021
Details:
The collaboration builds on previously published research pointing to a diversity of relevant biology within the gastrointestinal tract that can potentially be modulated with therapeutic proteins.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2021
Details:
The grant supports rapid development of an oral SARS-CoV-2 treatment and preventative product candidates through FDA Investigational New Drug (IND) submission and initial engineering work for a large-scale cGMP manufacturing plant.
Lead Product(s): Camelid antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: USAMRDC
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 24, 2020
Details:
The round brings Lumen’s total equity and non-dilutive investment to $68 million and will support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea.
Lead Product(s): LMN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: WestRiver Management
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
